We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+17.18%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.45B
AUM Growth
+$67.8M
Cap. Flow
-$174M
Cap. Flow %
-5.03%
Top 10 Hldgs %
43.57%
Holding
114
New
15
Increased
22
Reduced
33
Closed
19

Top Buys

Rank Stock Value
1
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$110M
2
AKRO
Akero Therapeutics
AKRO
+$64.9M
3
VIR icon
Vir Biotechnology
VIR
+$45.6M
4
MDT icon
Medtronic
MDT
+$40.2M
5
VRNA
Verona Pharma
VRNA
+$35.5M

Top Sells

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$142M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$137M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$94.1M
4
SNY icon
Sanofi
SNY
+$41.8M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$38.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.57%
2 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HLVX
101
DELISTED
HilleVax
HLVX
– –
-406,024
Closed -$6.71M
ISRG icon
102
Intuitive Surgical
ISRG
$126B
– –
-50,000
Closed -$12.8M
LRMR icon
103
Larimar Therapeutics
LRMR
$378M
– –
-2,280,709
Closed -$10.3M
SNY icon
104
Sanofi
SNY
$108B
– –
-768,101
Closed -$41.8M
TARA icon
105
Protara Therapeutics
TARA
$213M
– –
-290,051
Closed -$908K
TERN
106
DELISTED
Terns Pharmaceuticals
TERN
– –
-1,350,000
Closed -$15.7M
MORF
107
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-256,737
Closed -$9.66M
RAIN
108
DELISTED
Rain Oncology Inc. Common Stock
RAIN
– –
-1,648,215
Closed -$14.4M
CELL
109
DELISTED
PhenomeX Inc. Common Stock
CELL
– –
-2,506,442
Closed -$2.91M
BLU
110
DELISTED
BELLUS Health Inc.
BLU
– –
-4,952,538
Closed -$35.7M
RXDX
111
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
– –
-1,272,694
Closed -$137M
PEAR
112
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
– –
-900,548
Closed -$230K
ATNX
113
DELISTED
Athenex, Inc. Common Stock
ATNX
– –
-776,623
Closed -$1.03M
BLPH
114
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
– –
-930,000
Closed -$7.34M
1 2 3 4
5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q2 2023 Portfolio in Review

As of Q2 2023, Perceptive Advisors held 114 positions worth $3.45B, up 2% from $3.39B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Perceptive Advisors withdrew a net $174M in Q2 2023, closing 19 positions and reducing 33 holdings. Its most notable exit was Prometheus Biosciences, Inc. Common Stock, an estimated $137M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

Against the trend, Perceptive Advisors opened a new position in Medtronic worth $41.1M.

  • Perceptive Advisors's largest Q2 2023 buy was Medtronic: 467,000 shares worth $41.1M.
  • Perceptive Advisors added most to Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2023, an estimated $110M increase.
  • Perceptive Advisors's biggest Q2 2023 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $142M.
  • Perceptive Advisors fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $137M.
  • Perceptive Advisors's ten largest holdings make up 44% of its $3.45B portfolio in Q2 2023.
  • Perceptive Advisors opened 15 new positions and closed 19 in Q2 2023.
  • Perceptive Advisors's portfolio value rose 2% quarter-over-quarter to $3.45B.

Based on Perceptive Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.